EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids

Emanuele Frattini iD, Gaia Faustini, Gianluca Lopez iD, Emma Veronica Carsana, Mattia Tosi, Ilaria Trezzi, Manuela Magni, Giulia Soldà iD, Letizia Straniero, Daniele Facchi, Maura Samarani, Mitchell Martá-Ariza und 21 weitere

Brain · 2025

DOI: 10.1093/brain/awae365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Emanuele Frattini und 32 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy. Hauptthemen laut MEDLINE: Organoids, Glucosylceramidase, Parkinson Disease, Mesencephalon. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mizutani Foundation for Glycoscience, NIA NIH HHS, PRIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrillary aggregation of α-synuclein in Lewy body inclusions and nigrostriatal dopaminergic neuron degeneration define Parkinson’s disease neuropathology. Mutations in GBA1, encoding glucocerebrosidase, are the most frequent genetic risk factor for Parkinson’s disease. However, the lack of reliable experimental models able to reproduce key neuropathological signatures has hampered clarification of the link between mutant glucocerebrosidase and Parkinson’s disease pathology. Here, we describe an innovative protocol for the generation of human induced pluripotent stem cell-derived midbrain organoids containing dopaminergic neurons with nigral identity that reproduce characteristics of advanced maturation. When applied to patients with GBA1-related Parkinson’s disease, this method enabled the differentiation of midbrain organoids recapitulating dopaminergic neuron loss and fundamental features of Lewy pathology observed in human brains, including the generation of α-synuclein fibrillary aggregates with seeding activity that also propagate pathology in healthy control organoids. Concurrently, we found that the retention of mutant glucocerebrosidase in the endoplasmic reticulum and increased levels of its substrate, glucosylceramide, are determinants of α-synuclein aggregation into Lewy body-like inclusions, and the reduction of glucocerebrosidase activity accelerated α-synuclein pathology by promoting fibrillary α-synuclein deposition. Finally, we demonstrated the efficacy of ambroxol and GZ667161 (two modulators of the glucocerebrosidase pathway in clinical development for the treatment of GBA1-related Parkinson’s disease) in reducing α-synuclein pathology in this model, supporting the use of midbrain organoids as a relevant preclinical platform for investigational drug screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsGlucosylceramidaseParkinson DiseaseMesencephalonLewy BodiesHumansInduced Pluripotent Stem Cellsalpha-SynucleinDopaminergic NeuronsMutation

Stichwörter der Autor:innen

GBA1Lewy bodiesParkinson’s diseaseambroxolglucocerebrosidasemidbrain organoids

Substanzen

Glucosylceramidasealpha-SynucleinGBA protein, human

Autor:innen und Institutionen

  • Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
  • Division of Pathology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan 20122, Italy.
  • Department of Medical Biotechnology and Translational Medicine, University of Milano, Milan 20054, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20072, Italy.
  • Medical Genetics and RNA Biology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan 20089, Italy.

ORCID-Profile: Emanuele Frattini, Gianluca Lopez, Giulia Soldà, Jens C Schwamborn, Fabio Moda, Stefania Corti, Mario Bortolozzi, Thomas Wisniewski, Alessio Di Fonzo

Förderung

  • Mizutani Foundation for Glycoscience
  • NIA NIH HHS
  • PRIN
  • Dino Ferrari Center
  • Italian Ministry of Health
  • Fresco Institute for Parkinson's and Movement Disorders
  • Fondazione Cariplo
  • Fondazione Grigioni per il Morbo di Parkinson

Zitieren

APA

Frattini, E., Faustini, G., Lopez, G., Carsana, E. V., Tosi, M., Trezzi, I., Magni, M., Soldà, G., Straniero, L., Facchi, D., Samarani, M., Martá-Ariza, M., De Luca, C. M. G., Vezzoli, E., Pittaro, A., Stepanyan, A., Silipigni, R., Rosety, I., Schwamborn, J. C., …, & Di Fonzo, A. (2025). Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids. Brain. https://doi.org/10.1093/brain/awae365

Vancouver

Frattini E, Faustini G, Lopez G, Carsana EV, Tosi M, Trezzi I, et al. Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids. Brain. 2025. doi:10.1093/brain/awae365

BibTeX
@article{Frattini2025,
  author = {Frattini, Emanuele and Faustini, Gaia and Lopez, Gianluca and Carsana, Emma Veronica and Tosi, Mattia and Trezzi, Ilaria and Magni, Manuela and Soldà, Giulia and Straniero, Letizia and Facchi, Daniele and Samarani, Maura and Martá-Ariza, Mitchell and De Luca, Chiara Maria Giulia and Vezzoli, Elena and Pittaro, Alessandra and Stepanyan, Astghik and Silipigni, Rosamaria and Rosety, Isabel and Schwamborn, Jens C and Sardi, Sergio Pablo and Moda, Fabio and Corti, Stefania and Comi, Giacomo P and Blandini, Fabio and Tritsch, Nicolas X and Bortolozzi, Mario and Ferrero, Stefano and Cribiù, Fulvia Milena and Wisniewski, Thomas and Asselta, Rosanna and Aureli, Massimo and Bellucci, Arianna and Di Fonzo, Alessio},
  title = {Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awae365}
}
Kostenlos starten →